14 citations
,
January 2020 in “Biomaterials Science” Created microspheres show potential for safe and effective use in prostate artery embolization.
21 citations
,
October 1978 in “The Journal of Clinical Pharmacology” Levetiracetam and valproate sodium both reduce seizures when added to lamotrigine, but levetiracetam has fewer side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
January 2021 in “Asian Journal of Pharmaceutical and Clinical Research” FT-Raman spectroscopy is effective for identifying drug polymorphs, ensuring quality and stability.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
4 citations
,
June 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” A woman with Rhupus and Rowell syndrome was treated successfully with medication adjustments.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
20 citations
,
March 2017 in “Arthritis research & therapy” Social media can help compare the effectiveness and safety of new arthritis medications.
37 citations
,
August 2011 in “Journal of Bone and Mineral Research” A girl had rickets due to a gene mutation affecting vitamin D response.
May 2025 in “The Journal of Rheumatology” Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
14 citations
,
October 1977 in “The Lancet” 12 citations
,
October 1978 in “PubMed” Ro 10-9359 is an effective treatment for severe psoriasis but can cause side effects.
6 citations
,
January 2018 in “Pharmacoepidemiology and Drug Safety” Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
July 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
March 2025 in “Biomedical & Pharmacology Journal” Valproic acid is effective but often causes side effects like weight gain and hair loss, so personalized treatment is needed.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
A single dose of Platelet Rich Plasma effectively reduces symptoms of early knee osteoarthritis.
39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
The 1298CC genotype in RA patients leads to higher methotrexate toxicity, while the 1298AA genotype results in better treatment response.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.